The Alliance for Regenerative Medicine Commends Release of 21st Century Cures Discussion Document

– January 29, 2015

WASHINGTON, DC, January 28, 2015 – The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies industries, commends Chairman Fred Upton (R-MI) and Representative Diana DeGette (D-CO) for their work on the 21st Century Cures Initiative.

“We applaud Chairman Upton and Representative DeGette for taking this definitive step towards accelerating patient access to next-generation treatments and cures,” said Michael Werner, ARM’s executive director.

Werner continued, “We are encouraged to see ARM’s proposals incorporated into this draft document.  We will continue to push for a streamlined and clarified regulatory pathway specifically designed to safely and efficiently accelerate the approval of cell and gene therapy products.

“In addition, we will also continue to advocate for the establishment of a national Center of Excellence for regenerative medicine standards information, development, review and dissemination.  This Center will dramatically advance efforts to develop new therapies for patients.

“We look forward to working closely with the rest of the Committee, the full Congress and the wider medical, regulatory and patient advocacy community to ensure these products reach patients with unmet medical needs.”

For more information about ARM, please visit

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit